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INTRODUCTION 
Hypertrophic scars and keloids are dermal fibroproliferative disorders 
unique to humans that occur following trauma, inflammation, surgery, and that 
sometimes occur spontaneously  (Meenakshi et al.,2005). They are characterized by 
an excess development of collagen in the dermis and subcutaneous tissues.  Unlike 
the scar characteristics of normal wound repair, the exuberant scarring of keloid and 
hypertrophic scars results typically in disfigurement, contractures, pruritis and pain. 
Keloids occur in individuals with a familial disposition among Blacks, Hispanics and 
Orientals. 
Hypertrophic scars develop within the boundary of the original scar and 
may spontaneously regress over time, whereas keloids extend beyond the wound 
boundary and tend to remain elevated. Other differences between hypertrophic and 
keloid scars include histologic, morphologic and cellular response to growth factors, 
and scar appearance. These cutaneous fibrotic conditions can be caused by minor 
trauma to the skin, such as ear piercing, abrasion, tattooing and burns (English and 
Shenefelt, 1999). 
Clinically hypertrophic scars and keloids are characterized by excessive 
dermal fibrosis and scarring resulting from an imbalance in collagen synthesis and 
degradation during wound healing. Control of hypertrophic scars and keloids is a 
difficult challenge in surgical practice (Rockwel et al., 1989). Scars can cause 
functional and aesthetic problems during the operative and postoperative healing 
periods of    burn victims. More recently, abnormal interaction between epidermal 
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parenchymal cells and regulatory genes such as TP53 has been suggested   to be 
involved in the pathogenesis of hypertrophic scars and keloids (Teofoli et al., 1999). 
Scars occur more commonly in dark skinned individuals.   Wounds that cross skin 
tension lines, wounds located on the ear lobes, on the sternum or deltoid areas 
commonly show tendency for scarring. 
 Currently there are several accepted approaches for the reduction of 
hypertrophic scars and keloids. Each treatment has its various advantages and 
disadvantages in terms of efficacy, convenience and cost. The most common 
therapeutic approach is application of compression bandages for at least 6 to 
12months (Davie, 1985). Although application of silicon gel sheet    is effective in 
reducing hypertrophic scars and keloids (Fulton,1995) its application on certain 
anatomical locations  is difficult. Collagen, and mucopolysccharide creams (Magliaro 
et al., 1999), radiotherapy (Klumpar et al., 1994), laser therapy (Connell and Harland 
2000), interferon therapy (Berman and Flores, 1997), bleomycin  (Farahnaz et al, 
2005) and intralesional corticosteroids have been the cornerstone of treatment and 
prophylaxis of hypertrophic scars and keloids (Darzi et al.,1992). The most 
commonly used corticosteroid is tramicinolone acetonide (TAC) at a concentration of 
40mg/ml, 1ml of which is administered intralesionally. Corticosteroids act by 
suppressing inflammatory cell migration, and inhibition of fibroblast proliferation at 
high doses. Systemic absorption of corticosteroids may cause adrenal suppression. 
Local adverse effects include skin atrophy, telengiectasis, depigmentation and 
ulceration. Scar recurrence after stopping corticosteroid treatment is relatively 
common. 
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This study was been conducted to assess the efficacy of verapamil and 
triamcinolone in keloids and hypertrophic scars with regard to appearances, 
symptomatic improvement, patient satisfaction and complications. Verapamil has been 
shown to stimulate procollagenase synthesis in keloid, hypertrophic and normal human 
cultured fibroblasts, resulting in depolymerization of actin filaments, alteration of their 
cell shape, and reduction of the fibrous tissue production (Doong et al., 1996). 
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AIM 
  To determine whether the calcium channel blocker verapamil  has the 
potential to be used   for the treatment of keloids and hypertrophic scars in the future. 
 
OBJECTIVES 
• To evaluate the effects of Verapamil in the treatment of hypertrophic scars and  
keloids. 
•   To study the effect of verapamil on the rate of reduction of hypertrophic scars 
and keloids in comparison with triamcinolone.  
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REVIEW OF LITERATURE 
ANATOMY OF SKIN 
The skin is an ever-changing organ that contains many specialized cells 
and structures. The skin functions as a protective barrier. It is also very much 
involved in maintaining the proper temperature for the body to function well. It 
gathers sensory information from the environment, and plays an active role in 
immunological protection from disease. 
 Structure of the skin: 
The skin consists of the epidermis, dermis and subcutaneous tissue (Tortora 
and Grabowski.,1999). 
Figure 1 
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EPIDERMIS 
The epidermis is the outer layer of skin. The thickness of the epidermis 
varies in different types of skin. It is the thinnest on the eyelids at 0.05 mm and the 
thickest on the palm and soles at 1.5 mm. The epidermis contains 5 layers. From 
bottom to top the layers are named stratum basale, stratum spinosum, stratum 
granulosum, stratum lucidum, and stratum corneum. The bottom layer, the stratum 
basale, has cells that are shaped like columns. In this layer the cells divide and push 
already formed cells into higher layers. As the cells move into the higher layers, they 
flatten and eventually die. The top layer of the epidermis, the stratum corneum, is 
made of dead, flat skin cells that shed about every week. There are three types of 
specialized cells in the epidermis. The melanocyte produces the pigment melanin, the 
Langerhans' cell is the frontline defense of the immune system in the skin, and the 
Merkel's cell's function is unclear. 
DERMIS 
The dermis also varies in thickness depending on the location of the skin. 
It is 0.3 mm on the eyelid and 3.0 mm on the back. The dermis is composed of three 
types of tissues that are present throughout   and   not in layers. The types of tissue are 
collagen, elastic tissue, and reticular fibers.  
The two layers of the dermis are the papillary and reticular layers. The 
upper, papillary layer contains a thin arrangement of collagen fibers. The lower    
 17  
reticular layer is thicker and made of thick collagen fibers that are arranged parallel to 
the surface of the skin. 
 
The dermis contains many specialized cells and structures. The hair follicles are 
situated here with the erector pili muscle that attaches to each follicle. Sebaceous (oil) 
glands and apocrine (scent) glands are associated with the follicle. This layer also 
contains sweat glands, but they are not associated with hair follicles. Blood vessels 
and nerves course through this layer. The nerves transmit sensations of pain, itch, and 
temperature. There are also specialized nerve cells called Meissner's and Vater-Pacini 
corpuscles that transmit sensations of touch and pressure. 
 
SUBCUTANEOUS TISSUE 
The subcutaneous tissue is a layer of fat and connective tissue that contains 
relatively large blood vessels and nerves. This layer is important   for the regulation 
of temperature of the skin itself and the body. The size of this layer varies throughout 
the body and between individuals . 
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PHYSIOLOGY OF SKIN 
The skin is the largest organ of the body. The skin and its derivatives (hair, nails, 
sweat and oil glands) make up the integumentary system of the body. One of the main 
functions of the skin is protection (Guyton and Hall, 2005). Skin serves several 
functions, which are introduced here: 
Regulation of body Temperature : In response to high environmental temperature 
or strenuous exercise, the evaporation of sweat from the skin surface helps lower an 
elevated body temperature to normal. 
Protection :  The skin covers the body and provides a physical barrier that protects 
underlying tissues from physical abrasion, bacterial invasion, dehydration, and 
ultraviolet (UV) radiation. 
Sensation :  The skin contains abundant nerve endings and receptors that detect 
stimuli related to temperature, touch, pressure, and pain. 
Excretion :  Besides removing heat and some water from the body, sweat also is 
the vehicle for excretion of a small amount of salts and several organic compounds. 
Immunity :  Certain cells of the epidermis are important components of the 
immune system, which fends off foreign invaders.  
Blood Reservoir : The dermis of the skin houses extensive networks of blood vessels 
that carry 8 to 10% of the total blood flow in a resting adult.  
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Synthesis of Vitamin D :    Vitamin D is a group of closely related compounds.  
Synthesis of vitamin D begins with activation of a precursor molecule in the skin by 
ultraviolet (UV) rays in sunlight. 
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WOUND HEALING 
When any trauma violates cutaneous integrity, a provisional wound matrix 
is created to fill the physical defect. Starting with the formation of a blood clot, 
inflammatory cells, proliferating endothelial cells, fibroblasts and endothelial cells 
move along the wound matrix. They form new blood vessels, continue production of 
provisional extra cellular matrix and migrate from the wound edges to create a layer 
that covers the surface of the open wound .In the newly created matrix skin collagen 
fibrils and elastin fibrils form a supporting frame work. This framework is saturated 
with a filler substance composed of proteoglycans and glycoprotein, which mediates 
the interaction between the wound matrix and the wound healing cells. Finally the 
amount of collagen and their fibril cross-linking increases to provides the scar’s 
ultimate strength. 
STAGES OF WOUND HEALING 
Inflammatory stage occurs within hours of injury. Following the initial 
tissue injury, inflammatory mediators such as cytokines are released from the injured 
tissue cells and wound blood clot, which initiate the inflammatory stage.   The 
amount of blood released, the extent of devitalized tissue and the bacterial content 
largely control the intensity of the inflammatory process (Weigus et al.,1981). The 
length of time before wound closure is a critical factor in wound inflammation. 
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Proliferative Stage occurs within days of injury. During the proliferative stage, the 
number and density of fibroblasts in the extracellular matrix increase. New blood 
vessels and epithelium are formed. The balance between tissue degradation and 
biosynthesis permits remodeling of the provisional tissue and also determines the net 
amount of scar tissue produced (McGrath, 1990). 
Maturation stage occurs within months of injury. This   stage is characterized by 
cellular apoptosis and a shift in balance from scar remodeling toward scar degradation 
.The process is accompanied by extracellular matrix reorganization and reduction. 
Metalloproteases synthesized during the proliferation stage continue to break down 
the extracellular matrix at a rate largely determined by physical and biochemical 
factors in the matrix (McCauley et al.,1992). The amount of extracellular matrix 
biosynthesis is controlled by need for tissue strength and other operational 
parameters. Mechanical stress is an important contributory parameter in net scar 
production.  
In predisposed individuals, those wound healing processes show overabundant  
wound matrix responsible for raised, red and inflexible scar tissue which causes, 
itching, pain, functional limitation and cosmetic  problems. At a certain unknown 
point a derailment of the protecting wound healing process occurs and excessive scar 
tissue formation will be initiated. 
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HISTOLOGY OF HYPERTROPHIC SCARS 
AND  KELOIDS 
 
Keloids and hypertrophic scars differ from normal skin and normal scars by their rich 
vasculature, high mesenchymal cell density, and thickened epidermal cell layer. 
Collagen fibers are organized in swirls. Cosman et al., (1961) made a thorough and 
exhaustive study of the epidemiology of keloids, and set up guidelines  for the 
histological differentiation between hypertrophic scars and keloids. They suggested 
that the presence of broad eosinophilic refractile hyaline- like collagen fibers was the 
essential criterion for the diagnosis of keloids. Kischer and Brody (1981) suggested 
that the collagen nodule is the identifying structural unit of hypertrophic scars and 
keloids. The nodule, which is absent from mature scars, contains high density of 
fibroblasts and unidirectional collagen fibrils aligned in a highly stressed orientation 
(Craig ,1973).  
BIOCHEMICAL ANALYSIS OF ABNORMAL SCARS 
Studies of collagen, proteoglycan and water content of keloids and 
hypertrophic scars compared with normal skin have shown interesting differences. 
Total collagen content has been measured by hydroxyproline estimation method and 
the proteoglycan content has been measured by glucosamine estimation method 
(Elson and Morgan, 1933). 
Keloid tissue shows high levels of collagen, proteoglycan and water. The total 
collagen was fractionated into acid soluble and pepsin soluble portions and the 
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fractionated collagen was again estimated. Interestingly, here keloids show higher 
acid collagen than the pepsin soluble collagen. Hypertrophic scars and normal skin 
show higher pepsin soluble collagen. These observations show that though keloids 
show high amounts of collagen  their cross linking is very poor as the pepsin soluble 
fraction represents the cross-linked collagen. Apart from collagen and proteoglycans, 
the synthesis of other extra cellular matrix proteins has also been found to be much 
higher in keloids and hypertrophic scars. Excess matrix accumulation can occur not 
only by increased synthesis of extracellular matrix components but also by a 
reduction in matrix degradation,  either intracellular or extracellular. The ability of 
collagenases isolated from the scar fibroblast to degrade collagen has been studied 
with respect to hypertrophic scars and it has been shown that the activated 
hypertrophic scar fibroblasts have reduced ability to degrade collagen (Ghahary et 
al.,1998). 
The release and activation of growth factors during the inflammatory 
phase of healing are pre-requisites for subsequent processes, including angiogenesis, 
re-epithelialization, recruitment and proliferation of fibroblasts and matrix deposition. 
Angiogenesis is stimulated by endothelial chemo- attractants and mitogens that are 
released by mast cells, neutrophils, macrophages and keratinocytes (Kiristy, 1993). 
Wound re-epithelialization occurs following the migration of epithelial cells from the 
wound margin and epidermal appendages within the wound bed and is enhanced by 
EGF, TGF-β. Fibroblast  recruitment, proliferation and production of extra cellular 
matrix are influenced by the fibrogenic growth factors PDGF, IGF-I and TGF- β as 
well as basic fibroblast growth factor. These fibrogenic growth factors upregulate  
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extra cellular matrix production, increase the rate of proliferation and migration of 
fibroblast, and inhibit production of the proteases required to maintain the balance 
between production and degradation. TGF-β was initially isolated from human 
platelets but has since been shown to be produced at wound site by infiltrating 
lymphocytes, macrophages and fibroblasts. The TGF- β family consists of at least 
five highly conserved peptides, with TGF-β 1, TGF-β 2 , and TGF-β3  (Ando and 
Jense, 1993). 
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PATHOLOGICAL SCAR 
 
Excessive scar tissue was described in the Smith Papyrus about 1700BC. 
Albright was the first to describe it in 1806. He described it as a cancer - like tumor 
and referred to it as cancroid  later amending the term to cheloid. Alibert coined the 
term “cheloid” from the Greek word for “crab Claw”(Alibert,1961). Cosman et al, 
(1961) documented the presentation, characteristics, and treatment of keloids in the 
first systematic review of keloids in 1961. Mancini and Quaife (1962), and later 
Peacock et al., (1970) delineated the clinical differences between keloids and 
hypertrophic scars. 
Keloids are defined as scars within the skin that grow beyond the 
confines of the original wound. In contrast, hypertrophic scars are raised scars 
which remain within the boundaries of the wound. 
 
Hypertrophic scars 
The incidence of hypertrophic scars following surgery is about 40-70%, 
whereas it is higher (up to 91%) following burn injury (Deitch et al, 983). Several 
reports conclude that there is a substantial increased risk for hypertrophic scarring in 
burn wounds that take more than 21 days to heal. Hypertrophic scarring also occurs 
due to dynamic mechanical skin tension acting on the healing wound (e.g sternum, 
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deltoid and upper back (Curtis and Seehar, 1978). The natural history of hypertrophic 
scars is that they regress with time after injury, leaving behind, however, an unsightly 
wide gap of thinned dermis between wound edges. A familial pattern in hypertrophic 
scarring is not described. However populations with higher skin melanin content are 
known to have a higher incidence of hypertrophic scars. These populations include 
Africans, Asians, and Hispanics (Lewis and Sun ,1990). Hormonal   influences are 
also known to be important factors, with hypertrophic scarring often initated at the 
start of puberty or during pregnancy. Scar tissue cells are senstitive to the influences 
of the same growth factors that drive normal tissue growth and development. Schierle 
et al., (1997) demonstrated   an increase in testosterone receptors in hypertrophic 
scars, which may contribute to the formation of these scars during adolescence.  
Figure: 2 
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Keloid  Scars 
Although the diagnosis of keloids is often inappropriately applied to hypertrophic 
scars, the two lesions can be differentiated at several levels.  Unlike hypertrophic 
scars, the natural history of keloids is that they do not regress with time following 
injury. Keloid tumors grow to reach a certain size and may remain that size 
indefinitely. Patients with keloids also have an associated strong family history of 
keloids. Both autosomal dominant and recessive modes of transmission have been 
reported. Castagnoli et al, (1990) reported an association between keloid occurrence 
and HLA-BW16, BW21, and BW35.Most evidence suggests that keloid scarring is a 
genetic anomaly (Saya et al., 1999). The genetic basis for this disease is evidenced by 
the abherrant  behaviour  of fibroblasts  explanted from the scar tissue . Several 
investigators have demonstrated that the keloid fibroblasts exhibit abnormal 
regulation of apoptosis ( Akasaka and Ishikawa ,2000). It has also been reported   that 
keloid fibroblasts in vitro produce abnormally high levels of collagen, fibronectin, 
and proteoglycans, and display atypical responses to regulation by metabolic 
modulators, such as growth factors and hydrocortisone (Tredget et al., 1997). 
McCauley et al, (1992) reported increased serum levels of inflammatory cytokines in 
patients with keloids. Histologically, collagen bundles are thicker and more abundant 
in keloids and form a cellular node –like structure in the deep dermis. Fibroblasts 
isolated from keloids and hypertrophic scar exhibit increased gene transcription of 
alpha 1 procollagen. (Ueda et al., 1999) .A strong correlation exists between keloid   
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formation and age and sex hormones, with Fibroblasts isolated from keloids and 
hypertrophic scar. younger individuals being more vulnerable to their development.  
Figure :3 
KELOID SCAR 
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Location 
Keloids and hypertrophic scars are rarely found on the eyelids, genitalia, palms, or 
soles. Keloids do occur frequently, however, over the deltoid region, presternal 
area, and the upper back .They occur more frequently in areas where the skin is 
thick than in areas where the skin is thin (Crockett, 1964). 
Age 
Patients who   developed keloids or hypertrophic scars as children or teenagers may 
not exhibit this tendency in later life. Ketchum et al, (1974) proposed reasons for 
this phenomenon: younger individuals are more frequently subjected to trauma and 
younger skin possesses greater tensions, whereas older skin is less elastic and has 
more redundancy .The rate of collagen synthesis also is greater in younger persons. 
(Utto 1970;  Ketchum et al.,1974). 
Race 
Certain races such as   Africans and Asians   are more susceptible to hypertrophic 
scarring and keloid formation than Caucasians. Incidence ratios for the races vary 
from 5:1 to 15:1 (Cosman et al.,1961).  Koonin (1964) suggested that an aberration 
of the metabolism of   melanocyte stimulating hormone (MSH) may be responsible. 
He found deeply pigmented people of all races more prone to keloid formation than 
those with fair skin. 
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Scar Classification 
Mature scar -  Light colored   and flat. 
Immature scar - Red, sometimes itchy or painful, and slightly elevated in the 
process of remodelling. Many of these will mature normally over time and become 
flat. 
Linear   hypertrophic scar -  (e.g. surgical  or traumatic scar )  Red, raised 
sometimes itchy scar confined to the border of the original surgical incisions .This 
usually occurs within weeks after surgery. These scars may increase in size rapidly 
for 3-6 months and then, after a static phase, begin to regress. They generally 
mature to have elevated, slightly rope-like appearance with increased width, which 
is variable. The full maturation process may take up to 2 years. 
Wide spread hypertrophic scar (e.g. burn scar) A widespread red, raised 
sometimes itchy scar that remains within the border of the burn injury. 
Minor keloids - Focally raised, itchy scar extending over normal tissue. This may 
develop up to 1 year after injury and does not regress on its own. Simple surgical 
excision is often followed by recurrence. There may be a genetic abnormality 
involved in keloid scarring, typical sites including ear lobes.  
Major keloid – Large, raised (> 0.5cm) scar, possibly painful or pruritic and 
extending over normal tissue This often results from minor trauma and continues to 
spread over years (Thomas et al., 2002). 
 
 31  
 
TREATMENT  OF HYPERTROHIC SCAR 
AND   KELOIDS 
 
Reiffel (1995) has proposed the preventive use of adhesive sutures after 
any surgical incision. In a randomized controlled study, he demonstrated the utility of 
such preventive measures. A strategy of early clinical assessment can be considered 
as a good precautionary measure to prevent the pathologic evolution of scars, 
whatever be the origin of the scar and the intensity of the pathologic process. 
Regarding scar management, too many solutions have been proposed, some of which 
are inadequate. Reiffel concluded that silicone gel sheeting and intralesional 
corticosteroids are the only treatments for which sufficient evidence exists to make 
evidence based recommendations in the management of a wide variety of abnormal 
scars. Other standard practices and new emerging therapies need large scale studies 
with long term follow up before they can be recommended as alternative therapies. 
An appropriate classification of scars is a significant element because the differences 
in their clinical types determine the therapeutic approach. The existence of a variety 
of classification schemes is based on the need of optimal clinical reliability. Post-
trauma wound healing leads to different types of scars: normal scar; wide-stretched 
scar, atrophic scar, scar contracture, hypertrophic scar and keloid. 
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Surgery 
Surgical excision of hypertrophic scars or keloids is a common 
management option when used in combination with steroids with-or without silicone 
gel sheeting. However, excision of keloids on its own results in a high rate of 
recurrence of 45 to 50 % (Berman et al., 1997).  
Radiation therapy 
Radiation therapy has been used as monotherapy, and in combination with 
surgery, for hypertrophic scars and keloids. Response to radiotherapy alone is 10–
94% with a keloid recurrence rate of 50–100% (Lawrence, 1991). Such high 
recurrence rates are understandable given the resistance of these cases to other 
management options. Best results have been achieved with 1500 to 2000 rads over 5 
to 6 sessions in the early postoperative period (Norris, 1995). Most investigators 
agree that radiotherapy should be reserved for adults and for keloids resistant to other 
management modalities.  
Laser Therapy 
Laser therapy involves the use of   high-energy light to burn away 
damaged skin. Laser may be used to minimize wrinkles and fine scars .The newer 
flash lamp pumped pulse dye laser selectively decreases scar blood flow. Therefore 
flash lamp pumped pulsed dye laser loses efficacy in dark skinned individuals, who 
are at high risk for keloids ( Alster and West, 1995). 
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Cryotherapy 
Cryotherapy is a technique that uses specialized equipment to freeze scar tissue 
using liquid nitrogen. Cryotherapy results in microcirculatory disturbances leading to 
tissue damage, especially fibroblasts. Limitations include the delay of several weeks 
required for postoperative healing and the commonly occurring side effect of 
permanent hypopigmentation (Malakar and Malakar, 2000 ). 
Ultrasonic or microwave heating 
Ultrasonic or microwave heating is   used to soften the scar and decrease the 
tensile strength of a scar. It appears to reduce collagen content possibly by increasing 
collagenase activity, and some benefit is seen (Shamberger et al., 1981). 
Pressure Therapy 
Prolonged pressure on hypertrophic collagen has been reported to be effective in 
preventing recurrence of keloids after surgical treatment (Pollack, 1994). Garments 
made up of elasticized material are available for different anatomical areas of the 
body. Such garments are advised immediately after wound healing. 
Silicone Gel Sheeting 
Silicone gel sheeting has been a widely used clinical management option for 
hypertrophic scars and keloids since the early 1980s. Silicone gel sheeting may be 
especially useful in children and people who cannot tolerate the pain of other 
management procedures (Quinn, 1987). Some formulations of silicone oil have been 
 34  
shown to be effective on minor hypertrophic scars although these studies have 
limitations in their design (Wong et al., 1996 )  
Scar Massage 
This approach is usually combined with several other modalities. Massage 
therapy appears most beneficial in preventing contractures. However, massage also 
mechanically stimulates fibroblast synthesis of collagen (Car-Collins, 1992). 
 
Adhesive Microporous Hypoallergenic Paper Tape 
Applying paper tape with an appropriate adhesive to fresh surgical incisions   
for several weeks after surgery has been shown to be useful. The mechanism of this 
benefit is unknown, but may be mechanical and occlusive   (Reiffel, 1995).  
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PHARMACOLOGICAL APPROACHES TO  
HYPERTROPHIC AND KELOID  TREATMENT 
Retinoids 
Retinoids are synthetic derivatives of Vitamin A. Topical retinoids enhance 
epidermal proliferation while inhibiting proliferation of fibroblasts, and shift the 
healing process to normal regeneration. Adverse effects included photosensitivity, 
skin irritation in 50% of patients and skin atrophy in 10% of patients (Janssen, 1980). 
 
Imiquimod Therapy 
Imiquimod is a novel synthetic compound that is a member of the 
imidazoquinolone family of drugs. Imiquimod induces local production of interferons 
at the site of application. It is available as a 5% cream and is started immediately after 
surgery and continued daily for 8 weeks. The major side effect is mild to moderate 
irritation at the site of application. Hyperpigmentation occurs in 50 % of treated 
wounds (Jacob et al., 2003). 
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Tacrolimus 
Tacrolimus is an immunomodulator that inhibits TNF-alpha. gli-1, an 
oncogene, has been found to be overexpressed in fibroblasts of keloids. Rapamycin, a 
close analogue of tacrolimus, was used in an in vitro study and was found to inhibit 
the gli-1 oncogene, thus giving a rationale to initiate clinical trials of topical 
tacrolimus and rapamycin. Although the results were not statistically significant, the 
study showed a decrease in induration, tenderness, erythema, and pruritus for most 
keloids (Kim et al., 2001). 
Bleomycin 
Bleomycin in the dose of 1.5 IU/ml injected intralesionally through multiple 
pricks resulted in flattening of lesions in 6 of 13 cases (Espana et al., 2001.) 
Similarly, bleomycin has also been tried by Bodokh and Brun (1996) 
intralesionally, at monthly intervals to treat keloids. It was found to be effective but 
caused many side effects. Moreover, its high cost is a limiting factor. 
Vitamin E Cream 
Vitamin E is sometimes recommended for the self – management of scars. 
However there is no clinical evidence to suggest that it is effective (Nachbar and 
Korting, 1995). 
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Interferon 
Interferon α-2β, which has antiproliferative properties, was tried by Berman 
and Duncan (1989). They injected a keloid intralesionally with 1.5 million IU IFN 
α-2β twice a day for 4 days. The area of the keloid was found to be reduced to 50% 
of its original   size by day 9. IFN α-2β when also used post-operatively reduced the 
rate of recurrence to 19 % as compared to that of intralesional steroid, where the 
recurrence rate was 51%. 
Antihistamines 
Histamine antagonists, especially H1 antagonists, can relieve some of the 
burning and pruritus associated with keloids and may modulate keloid size.  H1 
blockers also   inhibit collagen synthesis (Cosman et al., 1982 ). 
 
Pencillamine, β -Aminopropiontrile and Colchicine 
 
Pencillamine, β -aminopropiontrile   are lysyl oxidase inhibitors that 
interfere with collagen cross- linking, making collagen more susceptible to 
collagenases. These oral agents are used with colchicine which increases 
collagenase activity (Meenakshi et al., 2005). 
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Intralesional 5-fluorouracil 
5-Fluorouracil injected intralesionally has been successfully used to treat 
small keloids. A mixture of 0.1 ml of triamcinolone acetonide (10 mg/ml) and 0.9 
ml of 5-FU (50 mg/ml) produces the best results. It is injected into the keloid 3 
times per week initially. Small keloids usually require a total of 5-10 injections 
given weekly. Painful injections are often the limiting factor. Recurrence is 
common after stopping the drug (Fitzpatrick, 1999). 
Verapamil 
Many organic calcium channel blockers (eg., verapamil ) induce collagenase 
production and scar tissue degradation .They induce changes in fibroblast gene 
expression, resulting in decreased collagen synthesis and increased collagenase 
production . These effects appear to be mediated by interruption of the basic 
cellular G protein signal transduction pathway that is critical to regulation of 
fibroblast behavior (Doong et al.,  1996).This pathway can be interrupted at 
multiple points by a wide range of commonly used drugs. Verapamil injected into 
the lesion has been shown to induce scar degradation in the skin, fascia and 
periocular tissue (Lee   and Ping, 1994).  
Triamcinolone 
Corticosteroids are effective in the majority of non-infected scars that 
exhibit symptoms such as pain and pruritus. Intralesional corticosteroids are 
believed to act by inhibiting fibroblast growth and decreasing alpha2 macroglobulin 
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levels, which lead to collagen degradation. Corticosteroid preparations used for 
intralesional injection have included hydrocortisone, triamcinolone, and 
dexamethasone, with none proving to be particularly advantageous. Several 
concentrations between 10 and 40 mg/ml can be used. In steroid-sensitive areas 
(e.g. nose, eyelids, lips) that can undergo dermal atrophy, 10 mg/ml should be used 
initially. After the initial dose, the patient should return after 3 to 4 weeks, and the 
injection should be repeated at a similar or higher dose if required. The local 
adverse effects of steroid injections are associated with the dose given. These are 
hypopigmentation, dermal atrophy, telangiectasia, necrosis, and ulceration. A major 
disadvantage of using intralesional corticosteroid is the pain associated with the 
injection, which can lead to patient noncompliance during follow- up (Sclafani et 
al., 1996). 
 
Inhibitors of Gene Transcription 
The antimetabolites mitomycin -c and 5- fluorouracil inhibit proliferation of 
cells by blocking DNA synthesis and transcription by competitive inhibition of 
thymidylate synthesis (Fitzpatrick, 1999). A single application in the first few days 
after wound closure appears to be effective. Antimetabolite - induced apoptosis has 
also been demonstrated in Tenon’s capsule fibroblasts (Crowston, 1998). 
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Growth factor inhibition. 
 
 
The transforming growth factor (TGF-β) family of proteins is centrally 
involved in regulating wound healing. The process of TGF-β synthesis and release 
is activated by injury and, along with the platelet-derived growth factor; it has a 
central and critical role in the induction of wound healing. The binding of TGF-β to 
its receptor on fibroblasts causes fibroblast proliferation, extracellular matrix and 
structural protein synthesis and TGF-β synthesis. Mannose-6-phosphate and several 
other disaccharides sterically limit TGF-β binding to its receptor and limit scar 
formation in experimental wound-healing models (Ferguson, 1994). 
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PHARMACOLOGY OF DRUGS  USED IN 
PRESENT STUDY 
Triamcinolone 
 
 
 
Triamciniolone structure 
Intralesional steroid, namely, triamcinolone, is the most effective and widely 
used treatment for keloids. Triamcinolone acetonide is a potent anti- inflammatory 
corticosteriod and is a  first line therapeutic drug for keloids. Large trials conducted 
in the 1960s and 1970s demonstrated that triamcinolone acetonide was effective in 
healing keloids in more than 80 % of cases (Hirshowitz et al., 1982). Triamcinolone 
inhibits the proliferation of normal fibroblasts and fibroblasts in keloids. It inhibits 
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collagen synthesis, increases collagenase production, and reduces tissue levels of 
collagenase inhibitors. Steroids also induce ultrastructural changes in collagen 
synthesis that enhance the organization of collagen bundles and degenerate the 
characteristic keloidal collagen nodules. Despite relatively few randomised, 
prospective studies there is a broad consensus that injected triamcinolone is 
effective for the treatment of keloids and hypertrophic scars and should be the first-
line therapy for the treatment of keloids and second-line therapy for the treatment of 
hypertrophic scars if other other treatments have failed (Alster and Willams, 1997; 
Griffith et al., 1970). 
Results are improved when corticosteroids are combined with other 
therapies such as surgery (Tang, 1992) and cryotherapy (Whang et al., 1997). 
Intralesional corticosteroid injection is associated with injection pain, even with 
standard doses of insoluble triamcinolone (40 mg/ml), and up to 63% of patients 
experience adverse effects that include skin atrophy, depigmentation and 
telangiectasias (Sproat et al., 1992). Topical steroid creams have been used with 
varying success, but absorption through an intact epithelium into the deep dermis is 
limited. A prospective, randomised study showed that topical steroids do not reduce 
scar formation in post-burn deformities (Yii, 1996). 
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Calcium channel blockers 
Verapamil 
 
 
Verapamil structure 
Hypertrophic scars and keloids are characterized by the overproduction and 
increased deposition of extracellular-matrix proteins  such as laminin, fibronectin, 
and collagen. The metabolism of cellular calcium ions (i.e., the intracellular 
concentration) may contribute to this production.  
Five calcium channel blockers (amlodipine, felodipine, manidipine, 
diltiazem, verapamil) significantly decrease collagen deposition in the extracellular 
matrix and inhibit the expression of various collagens (I, III, IV) in vitro. In 
addition to that, calcium channel blockers specifically increase the proteolytic 
activity of one type of collagenase (IV) (  Huang et al., 1999). 
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Verapamil, a widely used calcium channel blocker, has been shown to inhibit 
synthesis of extracellular matrix molecules, including collagen, glycosaminoglycans, 
and fibronectin .In addition, calcium channel blockers have been  reported to increase 
collagenase and transforming growth factor -β activity (Rehman et  al., 1998). Lee 
and Ping  (1990) reported that treatment of the fibroblast - populated collagen matrix  
with L- type voltage - gated  calcium channel blockers, verapamil hydrochloride, 
100µmol/L reduced  the incorporation of tritrated proline into the extra cellular 
matrix of the fibroblast - populated collagen matrix by almost 50 to 60%. 
Verapamil has been shown to stimulate procollagenase synthesis in keloids, 
hypertrophic and cultured normal human fibroblasts, resulting in depolymerization of 
actin filaments, alteration of their cell shape, and reduction of fibrous tissue 
production (Doong et al., 1996). Calcium antagonists alter cell shape and induce 
procollagenase synthesis in keloids and normal human dermal fibroblasts. The first 
successful results of the intralesional injection of verapamil were presented in 1994 in 
burn scars (Lee et al., 1994). 
 Verapamil hydrochloride was used for the treatment and prevention of recurrence of 
keloid and burn scars by local intralesional infiltration (D'Andrea et al., 2002). For 
stabilized keloids the results are poor compared to topical steroids. However, when 
verapamil was used following surgical excision of the keloid (2.5 mg/ml with doses 
ranging from 0.5 to 2.0 ml depending on the size) on postsurgical days 7, 14, 28, and 
during the second month, and combined with topical silicone layering without 
pressure therapy, there was a 54 % cure rate with absence of recurrence after 18 
months (Eray Copcu et al., 2004) 
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METHODOLOGY 
The study used a randomized, single blind parallel design to compare the 
effect of the calcium channel blocker verapamil and the corticosteroid 
triamcinolone on the healing of hypertrophic scars and keloids in two groups 
comprising 27 patients each. Patients who satisfied the selection criteria and gave 
written informed consent to participate in the study were chosen for the study. 
PATIENT  SELECTION  CRITERIA 
Inclusion criteria used : 
• Age  between  10 years  and 50 years 
• Atleast one hypertrophic  scar or  keloid   
• Scar on the body of size > 2   cm and < 10 cm. 
• Hypertrophic scar or keloid of less than 5 years duration 
  Types of scar that were included were due to : 
• Flame and acid burns 
• Wounds due to trauma or surgery  
• Insect bite  
• Acne  
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Exclusion criteria : 
• Family history of keloids 
• Dark pigmented skin  
• Pregnancy or lactation  
• Patients with other systemic illnesses like diabetes mellitus, cancer,  
          mental  disorders and cardiac diseases 
• Patients from outside Vellore District, Tamil Nadu 
Study Design Used:  
Patients were randomly allocated to receive intralesional injection of either 
1ml of verapamil (2.5mg) or 1ml of triamcinolone (40mg) once in 3 weeks. Clinical 
assessment of the scars were performed at the beginning of the study and at 3 week 
intervals after starting treatment. The drugs were administered till the scar flattened 
or for a maximum period of 6 months. The patients were asked to return for scar 
examination after 1year to check for any recurrence or complication 
The clinical assessment of the scar was based on the Vancouver Scar Scale 
which  is the  standard  scale used   universally for scar assessment (Mary Jo Baryza 
et al., 1995). This scale was slightly modified for the Indian patients. The scale 
scores the scars on four parameters namely pigmentation, vascularity , pliability, 
and height. In addition, the scar length, width and height also were measured using 
a centimeter scale .. 
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At each visit the patients' scars were photographed on a digital camera Nikon 
coolpix 3200.The patients were also given a proforma to assess their own response 
to the treatment they received in terms of itching, pain and color changes. This was 
mainly subjective. 
This study was conducted in the outpatients Department of Plastic and 
Reconstructive Surgery at the Christian Medical College and Hospital, Vellore. 
Determination of Sample Size: 
The sample size for the study was calculated to be 27 in each group on the basis of 
the alpha error of 0.05% (power of the study   was 80% ). This data is expressed as 
Mean ± S.E. 
Statistical Analysis of Data : 
For each study parameter in each group the mean value and standard error of mean 
(SEM) was calculated. The Wilcoxon Signed Rank Test was used for all statistical 
analyses of the data. Kaplan Meier  graphs & log rank test were done to compare the 
rate  at which all the study parameters reduced to zero (zero is considered as the   
event ),  with the two drugs . A   P value of less than 0.005 was considered to be 
statistically significant. 
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RESULTS 
 
54 patients fulfilled the selection criteria of the study and were selected for the 
study. Of these, 27 were randomly allocated to receive triamcinolone and the other 27 
were allocated to receive verapamil .The four parameters that were measured 
according to the modified Vancouver scale were Pigmentation, Vascualarity, 
Pliability and Height. The Vancouver scale and modified Vancouver Scale are 
included in the Annexure (Annexure 4).  
The demographic details of the two study groups are shown in Figure 4a,  4b 
and 5a, 5b. The mean age of the patients in the verapamil group was 26years and that 
in the triamcinolone group was 20 years. The male and female ratio in both study 
groups was the same .The etiology of scars of patients in both study groups is shown 
in Table 1.The location of scars of patients in both the groups is shown in Table 2. 
Each parameter of Vancouver scale were studied and were compared within the 
study groups serially upto 24 weeks and follow up was done  after 52 weeks. Tables : 
3a, 3b, 3c and 3d shows the effect of verapamil on the Vancouver scale parameters. 
The effects of triamcinolone  is shown in Tables 4a, 4b, 4c and 4d . In both study  
groups  there was  a reduction in vascularity, pliability and height (Tables: 3b, 3c and 
3d for Verapamil and Tables  4b, 4c and 4d for triamcinolone) during every third 
week .This reduction was maintained at 52 weeks also in the both study groups .A 
desired change in pigmentation was not seen with either of the two drugs(Table: 3a 
for verapamil and Table 4a for triamcinolone). In fact with triamcinolone , hyper 
pigmentation or hypo pigmentation were noticed in 25% of patients(Annexure 8 & 9). 
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Reduction in length, width and height as measured with a centimeter scale was 
studied in both groups during every 3rd week. Table 5 a, 5b and 5c  show the effects of 
verapamil and Tables 6a, 6b  and 6c show the triamcinolone effects There was reduction 
in width and height of the scar during every 3rd week in both groups. Length of the scar 
did not show any significant change in both the groups.  
The median time taken for reduction of all the parameters to zero was compared 
between the two drugs. Figures 6a, 6b, 6c and 6d compares the parameters of Vancouver 
scale and Figures 7a, 7b and 7c compares the parameters measured with a centimeter 
scale. Figure 6a shows that while comparing the median time taken for pigmentation to 
reduce to zero, there was no significant difference between the two drugs. Figures 6 b,   
6 c and 6 d show that the median time taken for reduction to zero in vascularity, 
pliability and height with triamcinolone was less as compared to verapamil and the 
difference was found to be significant. Figure 7a shows that the median time taken for 
reduction to zero in  length  is not significant in both the groups .Figure 7b and 7 c 
shows that the median time taken for reduction to zero in width and height as measured 
with triamcinolone  was less as compared to verapamil and the difference was found to 
be significant . 
Adverse drug reaction experienced by patients in each study groups are shown in 
Figure 8 and 9. Severe pain at injection site, hypopigmentation, irregular menstrual 
cycles and profuse sweating were complications observed with triamcinolone while  
profuse sweating and mild pain at the site of injection were seen with verapamil. Figure 
10a , 10b and 10c represent one patient’s  photograph in the verapamil group  and  
Figure 11a , 11b and 11c represent  one patient’s photograph in the  triamcinolone group. 
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F I G U R E  4 a 
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FIGURE  4 
Demographic Details of Verapamil Study Subject (n=27) 
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FIGURE: 5 
Demographic Details of Triamcinolone Study Subjects (n=27) 
 
Sex Distribution 
 
Age Distribution 
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TABLE  1 
ETIOLOGY OF SCARS IN EACH STUDY GROUP 
 Triamcinolone group 
(n=27) 
Verapamil group 
(n=27) 
Pimple 9 9 
Ear piercing 7 4 
Road traffic accident 7 11 
Surgery 4 2 
Post-vaccination 0 1 
 
 
 
TABLE  2 
LOCATION  OF   SCARS  IN  EACH  STUDY  GROUP 
 
 Triamcinolone Verapamil 
Face/Neck 2 4 
Ear lobe 7 2 
Sternum 8 4 
Abdomen/Chest 2 4 
Upper limb 5 10 
Lower limb 2 3 
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VANCOUVER SCAR SCALE 
TABLE No. 3 a 
EFFECTS OF VERAPAMIL ON SCAR PIGMENTATION 
(n= 27 in each group) 
 
Verapamil 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean 
(SEM in 
mm) 
2(0) 1.78(0.11) 0.04(0.03) 0(0) 0(0) 0(0) 
p value - 0.063a 0a 0a 0a NSb 
 
a : Compared to 0 week value 
b  : Compared to 24 week value 
 
NS: Not significant ( p > 0.005 ) 
 
TABLE No.3 b 
EFFECT OF VERAPAMIL ON SCAR VASCULARITY 
(n= 27 in each group) 
Verapamil 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean(SEM) in mm 1.81(0.16) 1.37(0.09) 0.26(0.08) 0(0) 0(0) 0(0) 
p Value - 0.001a 0a 0a 0a NSb 
 
 
a : Compared to 0 week value 
b  : Compared to 24 week value 
 
NS : Not significant ( p > 0.005 ) 
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VANCOUVER SCAR SCALE  
TABLE No. 3 c 
EFFECT OF VERAPAMIL ON SCAR PLIABILITY  
(n= 27 in each) 
Verapamil 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean (SEM) 
 in mm 2.33(0.14) 1.56(0.12) 0.3(0.09) 0(0) 0(0) 0(0) 
p Value - 0a 0a 0a 0a NSb 
 
 
    a : Compared to 0 week value 
    b  : Compared to 24 week value 
 
   NS : Not significant ( p > 0.005 ) 
 
 
TABLE No. 3 d 
EFFECT OF VERAPAMIL ON SCAR HEIGHT 
 (n= 27 in each) 
 
Verapamil 
 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean(SEM in mm)  1.63(0.09) 1.26(0.1) 0.19(0.07) 0(0) 0(0) 0(0) 
p Value - 0.002a 0a 0a 0a NSb 
 
a : Compared to 0 week value 
b  : Compared to 24 week value 
 
NS : Not significant ( p > 0.005 ) 
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VANCOUVER SCAR SCALE 
TABLE No.4 a 
EFFECTS OF TRIAMCINOLONE ON SCAR 
PIGMENTATION  (n=27 in each group) 
      Triamcinolone 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean 
(SEM) in 
mm 2(0) 1.52(0.14) 0.22(0.14) 0.22(0.09) 0.22(0.09) 0.22(0.09) 
p value - 0.004a 0a 0a 0a NSb 
 
   a : Compared to 0 week value 
   b  : Compared to 24 week value 
 
    NS : Not significant ( p > 0.005 ) 
 
TABLE No.4 b 
EFFECT OF TRIAMCINOLONE ON SCAR VASCULARITY 
(n= 27 in each group) 
 
   Triamcinolone 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean (SEM in mm) 1.89(0.09) 1.15(0.1) 0.07(0.05) 0(0) 0(0) 0(0) 
p Value  0a 0a 0a 0a NSb 
 
 
    a : Compared to 0 week value 
    b  : Compared to 24 week value 
 
    NS : Not significant ( p > 0.005 ) 
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VANCOUVER SCAR SCALE  
TABLE No.4 c 
EFFECT OF TRIAMCINOLONE ON SCAR PLIABILITY 
(n= 27 in each) 
Triamcinolone 
 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean (SEM) in 
mm 
2.26(0.11) 1.3(0.1) 0.04(0.03) 0(0) 0(0) 0(0) 
p Value - 0a 0a 0a 0a NSb 
 
 
     a : Compared to 0 week value 
     b  : Compared to 24 week value 
 
     NS : Not significant ( p > 0.005 ) 
 
TABLE No.4 d 
EFFECT OF TRIAMCINOLONE ON SCAR HEIGHT 
(n= 27 in each) 
 
Triamcinolone 
 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean (SEM) in 
mm 
1.67(0.1) 1.19(0.1) 0.07(0.05) 0(0) 0(0) 0(0) 
p value - 0.001a 0a 0a 0a NSb 
 
 
    a : Compared to 0 week value 
    b  : Compared to 24 week value 
 
   NS : Not significant ( p > 0.005 ) 
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CENTEMETER SCALE 
TABLE No.5 a 
EFFECTS OF VERAPAMIL ON SCAR LENGTH  
(n= 27 in each group) 
                                                      Verapamil 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52 wk 
Mean 
(SEM) 
in mm 
27.8(2.33) 23.3(2.28) 15.4(1.95) 12.4(1.66) 12.4(1.66) 12.4(1.66) 
p value  
- 
0a 0a 0a 0a NSb 
 
    a : Compared to 0 week value 
    b  : Compared to 24 week value 
 
   NS : Not significant ( p > 0.005 ) 
 
 
TABLE No. 5 b 
EFFECT OF VERAPAMIL ON SCAR WIDTH 
(n= 27 in each group) 
 
Verapamil 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean 
(SEM) in 
mm 
6.59(0.48) 5.26(0.54) 2.59(0.43) 1.81(0.25) 1.81(0.25) 1.81(0.25) 
p value - 0a 0a 0a 0a NSb 
 
     a : Compared to 0 week value 
     b : Compared to 24 week value 
     NS : Not significant ( p > 0.005 ) 
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CENTEMETER SCALE 
TABLE No. 5 c 
EFFECTS OF VERAPAMIL ON SCAR HEIGHT 
(n= 27 in each group) 
 
  Verapamil 
 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean(SE
M) in 
mm 
4.33(0.19) 3.229(0.2) 1.11(0.18) 0.15(0.07) 0.15(0.07) 0.15(0.07) 
p value - 0a 0a 0a 0a NSb 
 
        a : Compared to 0 week value 
        b  : Compared to 24 week value 
 
        NS : Not significant ( p > 0.005 ) 
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CENTEMETER SCALE 
TABLE No. 6 a 
EFFECTS OF TRIAMCINOLONE ON SCAR LENGTH 
(n= 27 in each group) 
                                                   
 Triamcinolone 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk                
 
52 wk 
Mean 
(SEM) in 
mm  27.1(2.65) 21.5(2.59) 14.4(1.97) 13.6(1.93) 13.6(1.93) 13.6(1.93) 
p value - 0a 0a 0a 0a NSb 
 
  a : Compared to 0 week value 
  b : Compared to 24 week value 
 
  NS : Not significant ( p > 0.005 ) 
 
 
TABLE No. 6 b 
EFFECT OF TRIAMCINOLONE ON SCAR WIDTH 
(n= 27 in each group) 
     Triamcinolone  
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean(SEM)in mm  6.89(0.51) 3(0.26) 0.33(0.11) 0(0) 0(0) 0(0) 
p value - 0a 0a 0a 0a NSb 
 
a : Compared to 0 week value 
b  : Compared to 24 week value 
NS : Not significant ( p > 0.005 ) 
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CENTEMETER SCALE  
TABLE NO 6 c 
EFFECTS OF TRIAMCINOLONE ON SCAR HEIGHT 
(n= 27 in each group) 
                                                   ( Plastic Scale ) 
 Triamcinolone 
 
 
Weeks 0 wk 3 wk 9 wk 18wk 24wk 52wk 
Mean(SEM) in 
mm 
4.52(0.17) 2.56(0.12) 0.22(0.08) 0(0) 0(0) 0(0) 
p value - 0a 0a 0a 0a NSb 
 
      a : Compared to 0 week value 
      b :  Compared to 24 week value 
      NS : Not significant ( p > 0.005 ) 
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KAPLAN MEIER  GRAPHS SHOWING THE RATE OF REDUCTION 
OF PARAMETERS BETWEEN THE TWO GROUPS BASED ON 
VANCOUVER SCALE. 
 
Figure 6a 
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Figure 6b  
 
 
VASCULARITY 
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Figure  6c 
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KAPLAN MEIER  GRAPHS SHOWING THE RATE OF REDUCTION 
BETWEEN THE TWO GROUPS AS MEASURED WITH A 
CENTEMETER  SCALE. 
 
Figure : 7 a 
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Figure : 7 b 
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Figure : 7 c 
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ADVERSE DRUG REACTIONS COMPARE 
BOTH THE GROUPS(N=27)  
Figure-8 
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TABLE 7 
COMPARING COST OF DRUGS FOR BOTH THE GROUPS 
TRIAMCINOLONE AND VERAPAMIL 
NAME OF DRUG COST PER MONTH 
TRIAMCINOLONE 
INJECTION Rs 55.72 /- 
VERAPAMIL INJECTION Rs.2/ 
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Figure  : 10a  
Verapamil – Pre Drug Assessment  
Subjects : 009 A( Photograph) 
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Figure : 10 b 
Verapamil   Post  drug Assessment at 18 weeks    
Subjects : 009 A(photograph) 
 
 
 
 
 
At 18 weeks  
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Figure: 10c 
Verapamil  Follow up Assessmentat 52 weeks  
Subjects : 009 A( Photograph) 
 
 
 
 
 
52 weeks  
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Figure  : 11a 
Triamcinolone – Pre Drug Assessment  
Subjects:  015 B( Photograph) 
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Figure  : 11b 
Triamcinolone – Post  Drug Assessment at 12 weeks  
Subjects:  015 B( Photograph) 
 
 
 
 
 
 
 
 
 
At 12 weeks  
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Figure  : 11c 
Triamcinolone – Follow up Assessment at 52 weeks 
 
 
Subjects:  015 B( Photograph) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 weeks  
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       DISCUSSION 
 
Hypertrophic scars and keloids are relatively common and important problems 
encountered in clinical practice. Inspite of many advances in the understanding of 
wound healing and scar formation, the treatment of these conditions is still 
controversial. ( Eray .Copcu et al.,  2004). 
There are several non pharmacological methods of treating hypertrophic 
scars and keloids but they have drawbacks such as high cost (silicone gel sheeting ) 
, poor efficacy ( surgery and laser  therapy) , recurrence(surgery ) and adverse 
effects like malignancy (radiation therapy).Pharmacological modes of treatment 
also have drawbacks such as poor efficacy (tacrolimus) , high cost (bleomycin and 
interferon ) recurrence (5-fluorouracil) and adverse  drug reactions (5 – fluorouracil, 
bleomycin , interferon and triamcinolone). 
  The prophylaxis of hypertrophic scar and keloid formation is more effective 
than its subsequent treatment. The prophylaxis involves the application of measures 
that reduce the risk of the development of problem-causing scars. 
The pathogenesis of keloid includes excessive amount of collagen and other 
extracellular matrix components ,Abergel et al., (1985 ) showed an abnormal 
composition and metabolism of collagen in hypertrophic scars and keloids. 
Calcium channel blockers were first used in collagen matrix on the 
connective tissue remodeling by Lee and Ping in 1990. Doong et al., (1996) 
presented their observation about calcium   channel blockers and claimed that they  
 77  
depolymerize actins filaments and alter the shape of fibroblast cells from bipolar to 
spherical and that this process results in an increase in procollagenase production. 
The first successful results of the intralesional injection of verapamil were 
presented in 1994 in burns scars (Lee et al.,1994). Lawrence, presented his 
experience with the intralesional verapamil injection and pressure therapy in the 
treatment of earlobe scars and reported the cure rate of 50%. Finally, D' Andrea et 
al., (2002) concluded that the treatment of keloids with perilesional surgical 
excision and topical silicone followed by an adjuvant treatment with intralesional 
verapamil hydrochloride injection at certain intervals offered a higher rate of 
resolution than other therapeutic strategies. For these reasons other modes of 
pharmacological therapy need to be evaluated.  
The present study has compared the efficacy of intralesional verapamil with 
that of intralesional triamcinolone in the treatment of hypertophic scars and keloids 
using a randomized, single-blind study design. It was not possible to use a double-
blind study design in the present study because triamcinolone is an oily emulsion 
whereas verapamil is a plain coloured solution. 
 It was found in the present study that intralesionally administered verapamil 
and triamcinolone exerted improvement in patients with hypertrophic scars and 
keloids. Clinical parameters of the scar such as  vascularity , pliablility  and height     
( measured using Vancouver scale) and width and height ( measured using centimeter  
scale ) showed improvement .The improvement was noted after 3 weeks of treatment 
with both triamcinolone and verapamil and was  present after one year of follow-up 
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after stopping treatment. Scar pigmentation was not changed desirably by either of 
the drugs. With triamcinolone, hypopigmentation or hyper pigmentation were noticed 
in some of the patients . Length of the scars were not altered significantly by both the 
drugs . 
 To this investigator’s knowledge this is the first randomized controlled study 
to demonstrate the efficacy of intralesional verapamil in the treatment of hypertophic 
scars and keloids. There have been other reports showing the efficacy of intralesional 
verapamil in the treatment of these disorders, but they have been case reports ( Lee et 
al., 1994 )or studies that used surgical treatment in conjunction with verapamil( 
D’Andrea et al., 2002 ;  Eray .Copcu et al., 2004 ). The results of the present study 
suggest that verapamil is clinically safe for patients with hypertrophic scars and 
keloids. When compared with other methods of treatment, injection of verapamil  
appears  to be capable of inducing a rapid beneficial effect in the scars.  
Verapamil, in addition to being found to be effective in treating 
hypertrophic scars and keloids in the present study, was also found to be less toxic 
than triamcinolone, causing a lower incidence of adverse drug reactions (Figure.8 
&9). Other advantages of verapamil over triamcinolone include the fact that the cost 
of verapamil is considerably less than that of triamcinolone and that verapamil 
(Table7 ), being a solution, is much easier to inject intralesionally than 
triamcinolone, which is an oily emulsion and causes severe pain at injection site. 
Hence verapamil may be a suitable alternative to triamcinolone in the treatment of 
hypertrophic scars and keloids, especially in the context of developing countries 
like India. 
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LIMITATIONS 
1. Double blind study could not be performed because triamcinolone is an oily 
emulsion whereas verapamil is a plain coloured solution. 
 
2. Hypertrophic scars were not distinguished from keloid scars using electron       
microscopy due to financial constraints. Electron microscopy would have 
given confirmation of the differences between hypertrophic scars and 
keloids. 
 
3. Recurrence rate was followed up for only 12 months in the present study 
due to time constraints. It would have been good to follow up the patients 
for  3 to 5 years. 
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SUMMARY AND CONCLUSIONS 
This study compared the efficacy of verapamil with that of triamcinolone in 
treating hypertrophic scars and keloids, both drugs given by injection 
intralesionally.  Triamcinolone is well established to be effective in treating these 
conditions but is known to have drawbacks like causing pain at the site of injection 
and causing adverse effects. It was found in the present study that verapamil, like 
triamcinolone, significantly improved all clinical parameters of the scars that were 
investigated. The improvement was observed after 3 weeks of treatment and was 
present one year after follow-up. Patient acceptability of verapamil was also found 
to be good and the incidence of adverse drug reactions was found to be lower in 
patients who received verapamil than in those who received triamcinolone. Hence, 
intralesional verapamil may be a suitable alternative to triamcinolone in the 
treatment of hypertrophic scars and keloids.   
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BURN SCAR ASSESSMENT 
VANCOUVER SCALE  ( Mary .Jo.Barzya  et al 1995) 
PATIENT NAME: 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                      VANCOUVER SCALE  
                                                                                                             MODIFIED  VANCOUVER SCALE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                        
 
 
PIGMENTATION (M) 
0 - Normal colour that closely resembles 
      to the body 
1 -  Hypopigmentation 
3 -  Hyperpigmentation 
 
VASCULARITY (V) 
0 – Normal Colour 
1 – brown 
2 –Pink 
3 –red 
PLIABILITY (P) 
0 – Normal  
1 – Supple – flexible with minimal     
       resistance 
2 -  Yielding – giving way to pressure 
3 -  firm – inflexible 
4 -  banding – rope – like tissue that 
       blanches with extension of scar 
5 -  contracture  
 
HEIGHT (H)                    Scale in mm 
0 - Normal – flat 
1 - < 2mm                       
2 - < 5mm  
3 -  > 5mm 
 
PIGMENTATION (M) 
0 - Normal colour that closely resembles 
      to the body 
1 -  Hypopigmentation 
3 -  Hyperpigmentation 
 
VASCULARITY (V) 
0 – Normal Colour 
1 -pink 
2 –red 
3 –purple 
PLIABILITY (P) 
0 – Normal  
1 – Supple – flexible with minimal     
       resistance 
2 -  Yielding – giving way to pressure 
3 -  firm – inflexible 
4 -  banding – rope – like tissue that 
       blanches with extension of scar 
5 -  contracture  
 
HEIGHT (H)                    Scale in mm 
0 - Normal – flat 
1 - < 2mm                       
2 - < 5mm  
3 -  > 5mm 
 
 92  
TABLE 12: 
SCAR - SCALE  ASSESSMENT  SCORES 
FOR VERAPAMIL  AND TRIAMCINOLONE 
Patient's  scar scale assessment score 
on improvent 
70.00%
72.00%
74.00%
76.00%
78.00%
80.00%
82.00%
84.00%
86.00%
Verapamil Triamcinolone
 
 
 
 
 
 
 
 
 
 
